Lantheus Holdings, Inc. $LNTH Shares Sold by Federated Hermes Inc.

Federated Hermes Inc. lessened its holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 8.1% in the second quarter, HoldingsChannel.com reports. The firm owned 286,748 shares of the medical equipment provider’s stock after selling 25,413 shares during the period. Federated Hermes Inc.’s holdings in Lantheus were worth $23,473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently modified their holdings of the company. Harbor Capital Advisors Inc. grew its stake in Lantheus by 24.7% during the 2nd quarter. Harbor Capital Advisors Inc. now owns 190,008 shares of the medical equipment provider’s stock worth $15,554,000 after buying an additional 37,691 shares during the last quarter. Reinhart Partners LLC. boosted its holdings in shares of Lantheus by 16.4% during the second quarter. Reinhart Partners LLC. now owns 1,403,659 shares of the medical equipment provider’s stock valued at $114,905,000 after acquiring an additional 197,719 shares during the period. Swedbank AB grew its position in shares of Lantheus by 11.0% during the first quarter. Swedbank AB now owns 1,228,743 shares of the medical equipment provider’s stock worth $119,925,000 after acquiring an additional 121,500 shares during the last quarter. Strs Ohio acquired a new stake in shares of Lantheus in the 1st quarter worth about $4,529,000. Finally, Select Equity Group L.P. lifted its position in Lantheus by 899.2% in the 1st quarter. Select Equity Group L.P. now owns 100,843 shares of the medical equipment provider’s stock valued at $9,842,000 after purchasing an additional 90,751 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Lantheus Price Performance

NASDAQ:LNTH opened at $60.88 on Wednesday. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The business’s 50-day moving average price is $55.92 and its 200 day moving average price is $63.25. Lantheus Holdings, Inc. has a 52-week low of $47.25 and a 52-week high of $111.29. The firm has a market cap of $4.04 billion, a P/E ratio of 25.58 and a beta of -0.10.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 earnings per share for the quarter. The company had revenue of $92.51 million during the quarter. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. As a group, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. The Goldman Sachs Group set a $77.00 target price on shares of Lantheus and gave the stock a “neutral” rating in a research report on Wednesday, October 8th. Weiss Ratings cut Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Truist Financial reaffirmed a “hold” rating and set a $61.00 target price (down previously from $63.00) on shares of Lantheus in a research note on Monday, November 10th. B. Riley decreased their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating for the company in a research note on Tuesday, September 16th. Finally, TD Cowen cut their price objective on shares of Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research note on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.17.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.